Acute Myocardial Infarction Market Report 2026

The acute myocardial infarction market size has grown strongly in recent years. It will grow from $1.56 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, increasing hospital and specialty cardiac centers, adoption of electrocardiogram and imaging techniques, growing awareness of acute mi symptoms, expansion of cardiac research initiatives.

The acute myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to development of novel thrombolytic agents, increasing use of minimally invasive procedures, adoption of advanced imaging technologies, growth of personalized cardiology treatments, integration of ai and big data in cardiac care. Major trends in the forecast period include increasing adoption of percutaneous coronary intervention (pci) procedures, rising use of advanced cardiac biomarkers for early diagnosis, growing focus on minimally invasive cardiac treatments, expansion of telecardiology and remote patient monitoring, increasing awareness and prevention programs for acute mi.

The rising cases of hypertension are expected to drive the growth of the acute myocardial infarction market going forward. Hypertension is a medical condition marked by consistently high blood pressure, which increases the risk of heart disease, stroke, and other health complications. The prevalence of hypertension is increasing due to sedentary lifestyles, including desk jobs, prolonged screen time, and minimal physical activity. Hypertension contributes to acute myocardial infarction by damaging arteries, promoting plaque buildup, and raising the risk of blood clots that can block coronary arteries. For instance, in September 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 1.4 billion adults aged 30-79 worldwide were living with hypertension in 2024, representing about one-third of the population in this age group. Therefore, the rising prevalence of hypertension is fueling the growth of the acute myocardial infarction market.

Major companies operating in the acute myocardial infarction market are focusing on obtaining regulatory approvals to expand their product portfolios, enhance treatment efficacy, and strengthen their market positions. Regulatory approvals refer to official authorizations from health agencies such as the FDA and EMA, ensuring that drugs and medical devices meet safety, efficacy, and quality standards before being marketed. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001, the world’s first developed for the emergency treatment of acute myocardial infarction (AMI). This designation recognizes SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic areas. With promising preclinical results showing benefits in recovery and reduced mortality, Fast Track status enables expedited FDA communication, accelerating the approval process and ensuring faster patient access to this innovative AMI therapy.

In February 2023, BioCardia Inc., a US-based biotechnology company, extended its partnership with CellProthera to develop ProtheraCytes for the treatment of acute myocardial infarction. The partnership aims to utilize BioCardia’s Helix transendocardial biotherapeutic delivery system for CellProthera’s ongoing Phase I/IIb EXCELLENT study of its lead product candidate, ProtheraCytes. CellProthera is a France-based biotechnology company focused on regenerative therapy for acute myocardial infarction (AMI).

Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc.

North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acute myocardial infarction market by increasing costs for imported stents, catheters, diagnostic equipment, and medications. Segments like percutaneous coronary intervention devices, thrombolytic agents, and imaging systems are most impacted, particularly in asia-pacific and europe where imports are significant. These tariffs have raised treatment costs and affected hospital procurement budgets. However, they have also promoted local manufacturing, encouraged cost-effective device innovations, and strengthened regional supply chain resilience.

The acute myocardial infarction market research report is one of a series of new reports that provides acute myocardial infarction market statistics, including acute myocardial infarction industry global market size, regional shares, competitors with a acute myocardial infarction market share, detailed acute myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the acute myocardial infarction industry. This acute myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute myocardial infarction (MI), commonly known as a heart attack, is defined by the death of heart muscle tissue due to a sudden reduction or complete stoppage of blood flow in one or more coronary arteries. This condition causes myocardial necrosis, most often resulting from the rupture of atherosclerotic plaques, which leads to acute obstruction of blood flow.

The main types of myocardial infarction are ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). STEMI is a severe form of heart attack caused by a complete blockage of a coronary artery, resulting in a major reduction of blood flow to the heart muscle. Treatment options for acute myocardial infarction include thrombolytic therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medications. Diagnosis is performed using electrocardiograms (ECG), cardiac biomarkers, echocardiography, coronary angiography, magnetic resonance imaging (MRI), and computed tomography (CT) scans. Medications and therapies can be administered orally, intravenously (IV), subcutaneously, transdermally, or sublingually. The primary end users include hospitals and clinics, ambulatory surgical centers, specialty cardiac centers, and research institutes.

The acute myocardial infarction market consists of revenues earned by entities by providing services such as diagnostic testing, telemedicine consultations, remote patient monitoring, pharmaceutical treatments, and post-acute myocardial infarction (AMI) management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute myocardial infarction market also includes sales of pharmaceutical drugs, medical devices, diagnostic tools, wearable cardiac monitors, and telemedicine platforms for remote cardiac care. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.